Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
€141.98
1.150%
The stock is one of the favorites of our community with 33 Buy predictions and 1 Sell predictions.
With a target price of 196 € there is a positive potential of 38.05% for Johnson & Johnson compared to the current price of 141.98 €.
